| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update CR Lee, JA Luzum, K Sangkuhl, RS Gammal, MS Sabatine, CM Stein, ... Clinical pharmacology & therapeutics 112 (5), 959-967, 2022 | 214 | 2022 |
| The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal … RM Cooper‐DeHoff, M Niemi, LB Ramsey, JA Luzum, EK Tarkiainen, ... Clinical Pharmacology & Therapeutics 111 (5), 1007-1021, 2022 | 147 | 2022 |
| Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association JW O’Sullivan, S Raghavan, C Marquez-Luna, JA Luzum, SM Damrauer, ... Circulation 146 (8), e93-e118, 2022 | 141 | 2022 |
| The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems JA Luzum, RE Pakyz, AR Elsey, CE Haidar, JF Peterson, M Whirl‐Carrillo, ... Clinical Pharmacology & Therapeutics 102 (3), 502-510, 2017 | 128 | 2017 |
| Pharmacogenomics of statins: understanding susceptibility to adverse effects JP Kitzmiller, EB Mikulik, AM Dauki, C Murkherjee, JA Luzum Pharmacogenomics and personalized medicine, 97-106, 2016 | 98 | 2016 |
| Pharmacogenomics of COVID-19 therapies T Takahashi, JA Luzum, MR Nicol, PA Jacobson NPJ genomic medicine 5 (1), 35, 2020 | 86 | 2020 |
| CYP3A4* 22 and CYP3A5* 3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort JP Kitzmiller, JA Luzum, D Baldassarre, RM Krauss, MW Medina Pharmacogenetics and genomics 24 (10), 486-491, 2014 | 63 | 2014 |
| Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants JA Talameh, JP Kitzmiller Journal of pharmacogenomics & pharmacoproteomics 5 (2), 2014 | 51 | 2014 |
| GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals JA Luzum, JP Kitzmiller, PJ Isackson, C Ma, MW Medina, AM Dauki, ... Cell metabolism 21 (4), 622-627, 2015 | 42 | 2015 |
| Moving pharmacogenetics into practice: it’s all about the evidence! JA Luzum, N Petry, AK Taylor, SL Van Driest, HM Dunnenberger, ... Clinical Pharmacology & Therapeutics 110 (3), 649-661, 2021 | 37 | 2021 |
| CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure JA Luzum, KM Sweet, PF Binkley, TJ Schmidlen, JP Jarvis, MF Christman, ... Pharmaceutical research 34, 1615-1625, 2017 | 37 | 2017 |
| Pharmacogenetics in chronic heart failure: new developments and current challenges JA Talameh, DE Lanfear Current heart failure reports 9, 23-32, 2012 | 37 | 2012 |
| Liquid chromatography–tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma J Wang, JA Luzum, MA Phelps, JP Kitzmiller Journal of Chromatography B 983, 18-25, 2015 | 32 | 2015 |
| Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new JA Talameh, HL McLeod, KF Adams Jr, JH Patterson Journal of cardiac failure 18 (4), 338-349, 2012 | 32 | 2012 |
| Physicians’ attitudes toward pharmacogenetic testing before and after pharmacogenetic education JA Luzum, MJ Luzum Personalized Medicine 13 (2), 119-127, 2016 | 31 | 2016 |
| Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations JA Luzum, E Theusch, KD Taylor, A Wang, W Sadee, PF Binkley, ... Journal of cardiovascular pharmacology 66 (1), 80-85, 2015 | 31 | 2015 |
| American Heart Association Council on Genomic and Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on … JW O’Sullivan, S Raghavan, C Marquez-Luna, JA Luzum, SM Damrauer, ... Circulation 146 (8), e93-e118, 2022 | 26 | 2022 |
| Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major US sources T Shugg, AL Pasternak, B London, JA Luzum NPJ genomic medicine 5 (1), 48, 2020 | 25 | 2020 |
| Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection JA Talameh, NL Rezk, ADM Kashuba Journal of Chromatography B 878 (1), 92-96, 2010 | 24 | 2010 |
| First-dose and steady-state pharmacokinetics of raltegravir in the genital tract of HIV negative women AE Jones, J Talameh, K Patterson, N Rezk, H Prince, ADM Kashuba 10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17, 2009 | 21 | 2009 |
